Introduction. The increase in the incidence of whooping cough in children and adults of different age groups justifies the need for their revaccination and the development of new, acceptable for these purposes. This work is devoted to substantiating the design of a clinical trial and describing the results of a comparative study of the safety and tolerability of the drug "GamLPV" with two-fold intranasal administration to healthy adult volunteers using two methods. The choice of the scheme and method of administration of the drug is justified. The serological structure of the population of adults aged 18–40 years living in Moscow and the Moscow region is characterized.Aim. Determination of the safety and tolerability of the drug with a double intranasal administration of the vaccine by drip method and spraying through an actuator.Materials and methods. A randomized placebo-controlled trial included 50 healthy male and female volunteers aged 18 to 40 years who met the inclusion criteria. The volunteers were divided into 2 groups of 25 people: a drip method of administration and spraying through an "actuator". By both methods, the drug was administered twice with an interval of 60 days.Results and discussion. Serological analysis of the population of healthy volunteers at the prescreening stage justified the inclusion in the study of volunteers containing anti-pertussis antibodies in the blood (IgG ≤40 Ed/ml). A comparison of the results of preclinical studies on an experimental model of non-human monkeys and the first phase of a clinical study of GamLPV allowed us to propose two methods of double administration of the drug as a promising vaccination scheme for volunteers. A comparative randomized study shows the safety of using the proposed scheme for vaccination of adult volunteers.Conclusions. Both proposed methods of double administration can be used to plan a multicenter study to research the immunogenicity and protective activity of GamLPV.
31 January 2025 in Biological Products. Prevention, Diagnosis, Treatment
INTRODUCTION. Currently used inactivated vaccines with acellular/whole-cell pertussis components do not provide sterilising or sufficiently long-lasting immunity, nor do these vaccines prevent the spread of the pathogen or infection. A live pertussis vaccine for intranasal administration, GamLPV, has passed the necessary preclinical studies and a clinical trial that established the optimal dose for single-dose vaccination.AIM. This study aimed to optimise the method and schedule of administration of the GamLPV intranasal live vaccine for pertussis prevention on the basis of the immunogenicity results obtained in a clinical trial involving healthy volunteers aged 18 to 40 years.MATERIALS AND METHODS. This blind, randomised, placebo-controlled clinical trial enrolled 50 healthy adults, who were then randomised into two groups according to the method of GamLPV administration (drops or spray). The study evaluated the efficacy of two administration schedules, including single-dose vaccination and double-dose vaccination with an interval of 60 days. The study analysed nasopharyngeal and oropharyngeal aspirates, serum samples, and peripheral blood mononuclear cells from volunteers. The levels of IgM, IgA, and IgG antibodies specific to Bordetella pertussis and the levels of secretory IgA antibodies were measured in serum samples and nasal aspirates, respectively, by enzyme-linked immunosorbent assay. Agglutinating antibody titres were determined by agglutination tests. The quantitative determination of B. pertussis DNA in aspirates used real-time polymerase chain reaction. Cell-mediated immune responses were assessed by the production of IFN-γ and IL-17 cytokines in peripheral blood mononuclear cells.RESULTS. GamLPV administration to volunteers induced B. pertussis-specific IgG and IgA antibodies observed in serum samples, secretory IgA antibodies identified in aspirates, and increased titres of total antibodies to B. pertussis measured by agglutination tests, regardless of the vaccination schedule and the method of administration. Repeated GamLPV administration had a pronounced booster effect, as evidenced by elevated titres of antibodies of all classes from day 14. Moreover, repeated vaccination reduced the time for clearance of B. pertussis bacteria compared with that after the first vaccination (from 28 to 14 days). There were no significant differences in the time courses and values of the measured parameters for nasal vaccine delivery by spray and drops.CONCLUSIONS. Intranasal vaccination with GamLPV induces pronounced humoral and cellular immune responses and nasal mucosal immunity against pertussis infection in adults. The recommended method for GamLPV administration is nasal drops. The accelerated clearance of bacteria observed after the second vaccination is indicative of sterilising immunity provided by the first vaccination, which can ultimately reduce pertussis transmission in the population.
14 December 2024 in Journal of microbiology, epidemiology and immunobiology
Introduction. The increase in incidence rate of pertussis worldwide, short-term insufficient immunity induced by acellular pertussis vaccines (TDaP) and their failure to provide antibacterial protection and to prevent transmission of infection in human population dictate the development of new pertussis vaccines. A new live recombinant pertussis vaccine for intranasal use (GamLPV) has completed preclinical studies in experiments on nonhuman primates and 2 phases of clinical trials involving adult healthy volunteers, in which the safety, immunogenicity and protective activity of the GamLPV were proven. Method and scheme of vaccine administration have been worked out. Aim. Confirmation of the immunogenicity and protective antibacterial potency of GamLPV in a randomized multicenter clinical trial on adult volunteers. Materials and methods. In this multicenter, clinical, randomized, placebo-controlled, double-blind study 260 healthy adults aged 18–65 years were divided into 2 groups: G1 — 210 volunteers (GamLPV) and G2 — 50 volunteers (placebo). 0.25 ml GamLPV delivered to each nostril (5 × 109 CFU) 60 days apart. Levels of Bordetella pertussis-specific IgG, IgA antibodies in blood serum and levels of B. pertussis-specific secretory IgA antibodies in nasopharyngeal aspirates were measured by ELISA method and agglutination test. The dynamics of elimination of attenuated B. pertussis bacteria after the first and second intranasal administration of GamLPV to volunteers was estimated by using qPCR. Results. Significant seroconversion of B. pertussis-specific IgG and IgA antibodies and growth of B. pertussis-specific secretory IgA antibody levels in nasal aspirates of volunteers were demonstrated. The dynamics of changes in the levels of IgG and IgA antibodies indicates a booster effect after second vaccination. Attenuated B. pertussis bacteria persist in the nose/oropharynx of vaccinated volunteers. The period of elimination after second vaccination is more than 2 times shorter than the period after the first one. The number of persistent B. pertussis bacteria after the second vaccination is less than 3% of the values after the first vaccination. Conclusion. High immunogenicity and the formation of antibacterial protection after single and double intranasal vaccination of GamLPV have been proven.
22 December 2024 in Biological Products. Prevention, Diagnosis, Treatment
INTRODUCTION. The current progressive increase in pertussis incidence and infant mortality rates is due to the insufficient effectiveness of existing vaccines, both in Russia and worldwide. Previous clinical trials showed that healthy adult volunteers developed long-term antibacterial immunity after vaccination with GamLPV, an intranasal recombinant live pertussis vaccine developed by the National Research Center for Epidemiology and Microbiology named after the honorary academician N. F. Gamaleya. Further clinical development of GamLPV in paediatric volunteers, including infants, requires preclinical studies in a newborn monkey model.AIM. This study aimed to evaluate the safety, immunogenicity, and protective efficacy of the GamLPV vaccine in infant hamadryas baboons (Papio hamadryas) challenged with pertussis after intranasal vaccination.MATERIALS AND METHODS. The study used 20 hamadryas baboons, including 7 infants aged 1–1.5 months, 7 mothers of these infants, and 6 control animals. The study examined the time course of changes in serum levels of specific IgG antibodies to pertussis toxin (PT) and filamentous haemagglutinin (FHA) by enzyme-linked immunosorbent assay (ELISA), monitored changes in serum levels of Bordetella pertussis antibodies by agglutination immunoassay, and detected B. pertussis DNA in oropharyngeal aspirates by real-time polymerase chain reaction.RESULTS. Intranasal GamLPV administration to infant baboons induced the production of specific IgG antibodies to PT and FHA (ELISA) and an increase in the total pertussis antibody titre (agglutination immunoassay). GamLPV did not cause any injection site or systemic reactions. There were no changes in complete blood counts and serum biochemistry profiles after vaccination. The protective efficacy of GamLPV against B. pertussis was demonstrated in challenge tests, where immunised animals had no clinical signs or laboratory findings indicative of pertussis in contrast to controls.CONCLUSIONS. The study demonstrated the safety and immunogenicity of the intranasal live pertussis vaccine GamLPV in newborn hamadryas baboons. GamLPV shows promise in the primary vaccination of infants, the revaccination of children and adults, and the development of herd immunity against pertussis in families.
29 June 2023 in Molecular Genetics Microbiology and Virology (Russian version)
Коклюш продолжает лидировать в группе управляемых инфекционных заболеваний, несмотря на массовую вакцинацию. В последние десятилетия отмечается значительный рост заболеваемости коклюшем, распространение атипичных форм среди подростков и взрослых. Предполагается, что формирование антропонозного источника инфекции происходит за счет бактерий Bordetella pertussis со сниженной или полностью утраченной вирулентностью, способных к длительной персистенции в организме человека и восстановлению инфекционности при определенных условиях. Механизмы персистенции возбудителя коклюша до сих пор не изучены. Мы полагаем, что одним из механизмов может быть нарушение оперона bvgAS, регулирующего экспрессию всех генов вирулентности бактерий B. pertussis, в результате интеграции IS-элементов. Мигрирующие IS-элементы, как известно, обладают способностью как встраиваться в сайты генома хозяина, так и вырезаться из них с восстановлением нарушенных функций. ЦЕЛЬ РАБОТЫ Оценка сроков персистенции и анализ состава популяций бактерий B. pertussis у больных коклюшем детей и контактных лиц в семейных очагах. МАТЕРИАЛ И МЕТОДЫ Обследованы 80 детей с подтвержденным диагнозом «коклюш» и 116 контактных с ними лиц в 59 семейных очагах. Пациентов включали в исследование после подписания информированного согласия. Для выявления ДНК B. pertussis в назофарингеальных мазках и регистрации интеграций IS-элементов использовали разработанную в НИЦЭМ им. Н.Ф. Гамалеи тест-систему ПЦР-РВ-IS, а также гнездовую ПЦР и секвенирование. РЕЗУЛЬТАТЫ Показана возможность длительного выявления возбудителя коклюша у больных на разных стадиях заболевания и у членов семей, контактировавших с больными. Установлено, что в периоде реконвалесценции коклюша у 25% заболевших наблюдается формирование инсерционных авирулентных bvg-мутантов B. pertussis в верхних дыхательных путях, способных к длительной персистенции в организме человека. С меньшей частотой (15%) формирование авирулентных мутантов регистрировали у контактных с больными лиц. ЗАКЛЮЧЕНИЕ Длительное выявление возбудителя коклюша и регистрация у бактерионосителей bvg-мутантов B. pertussis, содержащих интеграцию IS-элементов, подтверждают гипотезу о возможности перехода бактерий к персистенции в результате инсерционной инактивации оперона bvgAS. Выявление персистирующих бактерий и изучение механизмов их формирования важно для создания новой стратегии лечения и профилактики коклюша.
2 January 2026 in Epidemiology and Vaccinal Prevention
Relevance . A key feature of the modern pertussis epidemic is the increasing incidence of the disease against the backdrop of years of mass vaccination: since the mid-1950s, with whole-cell pertussis vaccines (WCPV) as part of the DPT vaccine, and since the 1990s, with acellular pertussis vaccines (aPV) as part of the DTaP vaccine in many economically developed countries. The immune response that develops after whooping cough persists for up to 20 years, compared to 4 to 14 years after WCPV vaccination, and up to 6 years after APV vaccination. Aim . Assessment of the safety of the live recombinant pertussis vaccine «GamLPV» in a multicenter, blind, randomized, placebo-controlled study with double intranasal administration to adult volunteers. Materials and methods . The study involved 260 adult volunteers aged 18 to 65 years: 210 people in the study «GamLPV» group and 50 people in the «Placebo» group. The vaccine «GamLPV» was administered in a dose of 4.5 x 109 CFU intranasally twice with an interval in 60 ± 5 days, as well as the comparison drug (Placebo). Safety and tolerability were assessed based on data on the frequency of registration, nature and severity of adverse events (AEs) with a double intranasal drug administration of the vaccine. Results and discussion . During the study, no serious and severe AEs were registered. The analysis of the registered AEs did not confirm a reliable dependence on the administration of the GamLPV and, when compared with placebo, did not reveal statistically significant differences. We show that there was no statistically significant difference in safety parameters between the compared groups of volunteers who administered the GamLPV or placebo. The data from laboratory and instrumental examinations did not reveal significant deviations from the norm and the difference between the «GamLPV» and «Placebo» groups. Conclusions The results of the phase III of clinical trial vaccine in adult volunteers indicate good tolerability and a high safety profile of the GamLPV vaccine. Based on the conducted research, permission was obtained from the Ministry of Health of the Russian Federation for a new clinical trial of the GamLPV with the participation of volunteers aged 6 and 14 years.